Tomáš Hanke, HIVR4P 2021: T cell Vaccines for HIV-1 Infection (Part 1)
It was a pleasure to speak with Tomáš Hanke (University of Oxford, Oxford, UK) to discuss his recent work in T cell responses in HIV to inform vaccine development.
His abstract entitled: ‘Refocusing T cell responses with therapeutic vaccination strategies’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021.
Part 1 of our discussion can be viewed here.
- What are the aims of your research? (0:19)
- How can vaccines exploit vulnerability of the HIV virus? (0:50)
- Could you tell us a little about the design of the vaccines you have developed? (1:40)
- What is the current status of development of these vaccines? (2:52)
- What further studies are planned? (4:10)
Disclosures: Tomáš Hanke is a QA coinventor on a patent protecting the use of the conserved mosaic vaccines.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the HIVR4P Virtual Conference 2021.
Share this Video
Related Videos In Viral Infections
DANFLU-1: post-hoc analysis of high-dose quadrivalent influenza vaccines: Niklas Dyrby Johansen, ECCMID 2023
DANFLU-1 was an open-label, active-controlled, individually randomized trial conducted in Denmark during the 2021/2022 northern hemisphere influenza season. Dr Niklas Dyrby Johansen (University of Copenhagen Copenhagen, Denmark) discusses the post-hoc analysis from DANFLU-1 which investigated the effects of high-dose quadrivalent influenza vaccine (QIV-HD) vs standard-dose quadrivalent influenza vaccine (QIV-SD). The abstract ‘Relative effectiveness of high-dose […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results
Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the findings from an ongoing phase 3 study investigating vaccine efficacy of the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!